Oncotarget

Research Papers:

Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity

Manh-Cuong Vo, Hyun-Ju Lee, Jong-Seok Kim, My-Dung Hoang, Nu-Ri Choi, Joon Haeng Rhee, Vinoth-Kumar Lakshmanan, Sung-Jae Shin and Je-Jung Lee _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:33781-33790. https://doi.org/10.18632/oncotarget.5281

Metrics: PDF 1410 views  |   HTML 1696 views  |   ?  


Abstract

Manh-Cuong Vo1, Hyun-Ju Lee1,2, Jong-Seok Kim3, My-Dung Hoang1, Nu-Ri Choi1, Joon Haeng Rhee4, Vinoth-Kumar Lakshmanan5, Sung-Jae Shin3, Je-Jung Lee1,2

1Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital, Jeollanamdo, Republic of Korea

2Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Republic of Korea

3Department of Microbiology and Institute of Immunology and Immunological Diseases, Yonsei University, Seoul, Republic of Korea

4Department of Microbiology, Chonnam National University Medical School, Gwangju, Republic of Korea

5Department of Biomedical Science, Chonnam National University Medical School, Gwangju, Republic of Korea

Correspondence to:

Je-Jung Lee, e-mail: drjejung@chonnam.ac.kr

Keywords: dendritic cells, mycobacterial heat shock protein 90, mouse colon cancer

Received: June 04, 2015     Accepted: September 04, 2015     Published: September 16, 2015

ABSTRACT

Dendritic cell (DC)-based vaccines are considered useful in cancer immunotherapy, and the interaction of DC and adjuvants is important in the design of the next generation vaccines. In this study, whether DC combined with Rv2299c derived from mycobacteria could improve anti-tumor immune responses in a colon cancer mouse model was evaluated. MC38 cell lines were injected subcutaneously to establish colon-cancer-bearing mice and the following four groups were evaluated: PBS control, tumor antigen (TA) loaded-DC, Rv2299c, and a combination of TA-loaded-DC and Rv2299c. The combination treatment with TA-loaded-DC and Rv2299c exhibited greater inhibition of tumor growth compared to other groups. These effects were associated with the reduction of suppressor cells, such as myeloid-derived suppressor cells and regulatory T cells, and the induction of effector cells, such as CD4+ T cells and CD8+ T cells, in spleen, and with the activation of cytotoxic T Lymphocytes and NK cells. These results suggest that TA-loaded-DC vaccination with Rv2299c derived from mycobacteria enhanced anti-tumor immunity in a mouse colon cancer model by inhibiting the generation of immune-suppressive cells and recovering numbers of effector cells, and demonstrated superior polarization of the Th1/Th2 balance in favor of the Th1 immune response.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5281